Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy

Medical Hypotheses

Volumn 55, Issue 3, 2000, Pages 189-194

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE; METHOTREXATE; NICOTINIC ACID;

DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SKELETAL MUSCLE;

EID: 0033796159     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.1011     Document Type: Article

References (69)

1. New developments in the use of niacin for treatment of hyperlipidemia: New considerations in the use of an old drug
2. Treatment of hyperlipidemia with combined niacin-statin regimens
3. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men
4. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease
5. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
6. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
7. Hepatic toxicity of unmodified and time-release preparations of niacin
8. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
9. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase
10. Effects of niacin therapy that simulate neoplasia: Hepatic steatosis with concurrent hepatic dysfunction
11. Differences in metabolism of time-release and unmodified nicotinic acid: Explanation of the differences in hypolipidemic action?
12. Determination of niacin metabolites 1-methyl-5-carboxylamide-2-pyridone and N-1-methylnicotinamide in urine by high-performance liquid chromatography
13. Biochemical markers for assessment of niacin status in young men: Urinary and blood levels of niacin metabolites
14. Labile methyl balances for normal humans on various dietary regimens
15. Creatine in humans with special reference to creatine supplementation
16. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine
17. Hepatic toxicity from large doses of vitamin B3 (nicotinamide)
18. Metabolic effects and liver damage after prolonged administration of high doses of nicotinamide to rats
19. Metabolic effects of nicotinamide administration in rats
20. Hepatic content of S-adenosylmethionine, S-adenosylhomocysteine and glutathione in rats receiving treatments modulating methyl donor availability
21. Muscle creatine content in rats given repeated large doses of nicotinamide: Effects of dietary methionine, choline, carnitine, and other supplements
22. Nicotinamide megadosing increases hepatic poly(ADP-ribose) levels in choline-deficient rats
23. Acute dose-dependent disposition studies of nicotinic acid in rats
24. Nicotinamide methylation and its relation to NAD synthesis in rat liver tissue culture. Biochemical basis for the physiological activities of 1-methylnicotinamide
25. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects
26. Effects of prolonged ethanol feeding on methionine metabolism in rat liver
27. Methotrexate hepatotoxicity
28. Human betaine-homocysteine methyltransferase is a zinc metalloenzyme
29. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
30. The effect of betaine in reversing alcoholic steatosis
31. Interaction of methotrexate with lipotropic factors in rat liver
32. Chronic toxicity of methotrexate in rats: Partial to complete projection of the liver by choline: Brief communication
33. Betaine, metabolic by-product or vital methylating agent?
34. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon
35. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases
36. Creatine and creatinine metabolism in the normal male adult studied with the aid of isotopic nitrogen
37. Metabolic control of creatine synthesis. I. Effect of dietary creatine
38. Dietary intakes and urinary excretion of calcium and acids: A cross-sectional study of women in China
39. Liver choline oxidase activity in man and in several species of animals
40. Methionine metabolism in mammals: The biochemical basis for homocystinuria
41. Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat
42. Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease
43. Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency
44. Clinical results using betaine citrate (Flacar) in fatty livers
45. Clinical experience with betain citrate (author's transl)
46. Treatment of liver diseases, especially of fatty liver with betaine citrate
47. Betaine reduces hepatic lipidosis induced by carbon tetrachloride in Sprague-Dawley rats
48. The recovering effect of betaine on carbon tetrachloride-induced liver injury
49. Effect of trimethylglycine on lipid metabolism in experimental atherosclerosis in rabbits
50. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons
51. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders
52. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM
53. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus
54. Insulin sensitivity is increased in Friend erythroleukemia cells enriched in polyunsaturated fatty acid
55. Hyperinsulinemia is related to erythrocyte phospholipid composition and membrane fluidity changes in obese nondiabetic women
56. Lipid effects on the binding properties of a reconstituted insulin receptor
57. Skeletal muscle phosphatidylcholine fatty acids and insulin sensitivity in normal humans
58. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats
59. Alterations in hepatocyte insulin receptors in rats fed a choline-deficient diet
60. Lowering plasma free fatty acid levels improves insulin action in conscious pregnant rabbits
61. Lowering of plasma glucose in diabetic rats by antilipolytic agents
62. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period
63. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiclogic rationale for nighttime dosing
64. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
65. Methotrexate: The emerging drug of choice for serious rheumatoid arthritis
66. Methotrexate: Adverse reactions and major toxicities
67. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases
68. A population based strategy to prevent insulin-dependent diabetes using nicotinamide
69. The effect of niacinamide on osteoarthritis: A pilot study